Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Bruce E Brockstein"'
Autor:
Ramesh K Wali, Dhananjay P Kunte, Mart De La Cruz, Ashish K Tiwari, Jeffrey Brasky, Christopher R Weber, Tina P Gibson, Amir Patel, Suzana D Savkovic, Bruce E Brockstein, Hemant K Roy
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e38047 (2012)
Head and neck squamous cell carcinoma (HNSCC) is a major cause of morbidity and mortality underscoring the need for safe and effective chemopreventive strategies. Targeting epidermal growth factor receptor (EGFR) is attractive in that it is an early
Externí odkaz:
https://doaj.org/article/9f641abb2fa548c69e69a6c6d5ad08d7
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 2, Iss , Pp 100031- (2020)
Many advanced cancers, such as melanoma, evade the immune system by exploiting negative feedback mechanisms. Immune checkpoint inhibitor (ICI) therapy dramatically enhances immune surveillance and has revolutionized treatment of advanced melanoma. Ho
Externí odkaz:
https://doaj.org/article/07dfaf9ebf384b83807c2cf9b42d7e4b
List of TCGA samples included in this study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b5a716ad71e0c03f1493d31302f8b80
https://doi.org/10.1158/2326-6066.22538509
https://doi.org/10.1158/2326-6066.22538509
List of 1,015 genes used for identification of T cell-inflamed, intermediate, and non-T cell-inflamed tumor subtypes.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08665164fccf6c769d53092b2d9cb9ae
https://doi.org/10.1158/2326-6066.22538506.v1
https://doi.org/10.1158/2326-6066.22538506.v1
Anti–Programed Death 1 (PD-1) is standard immunotherapy for multiple cancers, and the expression of one of its ligands, PD-L1, has been described in germ cell tumors (GCT). Neither the clinical activity of anti–PD-1 nor the incidence of an immuno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3155cae04e52ba7fc273003a64798c0
https://doi.org/10.1158/2326-6066.c.6548803.v1
https://doi.org/10.1158/2326-6066.c.6548803.v1
Significant biological processes (FDR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ef4a570426f325e6cd8a3d23a8ca1e1
https://doi.org/10.1158/2326-6066.22538503
https://doi.org/10.1158/2326-6066.22538503
Publikováno v:
Sarcoma, Vol 3, Iss 2, Pp 95-99 (1999)
Discussion. Oncogenic osteomalacia is a rare paraneoplastic syndrome of skeletal demineralization from renal phosphate loss. Patients with this disorder have the characteristic clinical, laboratory, and radiographic findings of hyperphosphaturic o
Externí odkaz:
https://doaj.org/article/a910df2db6d04415ab3db0919daa405d
Autor:
Bruce E, Brockstein, Everett E, Vokes
Publikováno v:
Nature reviews. Clinical oncology. 8(2)
Outcomes for patients with oropharyngeal cancer are determined by their tumor characteristics and associated demographics. The role of human papilloma virus-related disease for prognosis and outcomes with chemoradiotherapy is being more clearly defin
Autor:
Arlene A, Forastiere, Kie-Kian, Ang, David, Brizel, Bruce E, Brockstein, Barbara A, Burtness, Anthony J, Cmelak, Alexander D, Colevas, Frank, Dunphy, David W, Eisele, Helmuth, Goepfert, Wesley L, Hicks, Merrill S, Kies, William M, Lydiatt, Ellie, Maghami, Renato, Martins, Thomas, McCaffrey, Bharat B, Mittal, David G, Pfister, Harlan A, Pinto, Marshall R, Posner, John A, Ridge, Sandeep, Samant, David E, Schuller, Jatin P, Shah, Sharon, Spencer, Andy, Trotti, Randal S, Weber, Gregory T, Wolf, Frank, Worden
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN. 6(7)
Autor:
Daniel J, Haraf, Fred R, Rosen, Kerstin, Stenson, Athanassios, Argiris, Bharat B, Mittal, Mary Ellyn, Witt, Bruce E, Brockstein, Marcy A, List, Louis, Portugal, Harold, Pelzer, Ralph R, Weichselbaum, Everett E, Vokes
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 9(16 Pt 1)
Induction chemotherapy with carboplatin and paclitaxel followed by concomitant TFHX (paclitaxel, infusional 5-fluorouracil, hydroxyurea, and twice-daily radiation therapy administered every other week) has resulted in 70% 3-year survival in stage IV